JCO:顺铂治疗与晚期实体瘤患者VTE发生风险增高相关
2012-12-10 JCO JCO
美国一项荟萃分析显示，使用顺铂治疗与晚期实体肿瘤患者出现静脉血栓栓塞（VTE）风险显著增加有关。文章11月13日在线发表于《临床肿瘤学杂志》（J Clin Oncol）。 研究共纳入38项随机对照试验中患不同类型的晚期实体瘤患者。使用顺铂与不使用顺铂的患者，VTE的发生率分别为1.92%和0.79%。接受以顺铂为基础的化疗，可显著增加VTE的发生风险（RR=1.67，
美国一项荟萃分析显示，使用顺铂治疗与晚期实体肿瘤患者出现静脉血栓栓塞（VTE）风险显著增加有关。文章11月13日在线发表于《临床肿瘤学杂志》（J Clin Oncol）。
研究共纳入38项随机对照试验中患不同类型的晚期实体瘤患者。使用顺铂与不使用顺铂的患者，VTE的发生率分别为1.92%和0.79%。接受以顺铂为基础的化疗，可显著增加VTE的发生风险（RR=1.67，P=0.01）；亚组分析显示，每周顺铂剂量＞30 mg/m2的患者（RR=2.71）及2000~2010年入选试验的受试者（RR=1.72）出现VTE的相对风险最高。
Purpose
Several reports suggest that cisplatin is associated with an increased risk of thromboembolism. However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemotherapy has not been well described, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of VTEs associated with cisplatin-based chemotherapy.
Methods
PubMed was searched for articles published from January 1, 1990, to December 31, 2010. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based versus non–cisplatin-based chemotherapy in patients with solid tumors. Data on all-grade VTEs were extracted. Study quality was calculated using Jadad scores. Incidence rates, relative risks (RRs), and 95% CIs were calculated using a random effects model.
Results
A total of 8,216 patients with various advanced solid tumors from 38 randomized controlled trials were included. The incidence of VTEs was 1.92% (95% CI, 1.07 to 2.76) in patients treated with cisplatin-based chemotherapy and 0.79% (95% CI, 0.45 to 1.13) in patients treated with non–cisplatin-based regimens. Patients receiving cisplatin-based chemotherapy had a significantly increased risk of VTEs (RR, 1.67; 95% CI, 1.25 to 2.23; P = .01). Exploratory subgroup analysis revealed the highest RR of VTEs in patients receiving a weekly equivalent cisplatin dose > 30 mg/m2 (2.71; 95% CI, 1.17 to 6.30; P = .02) and in trials reported during 2000 to 2010 (1.72; 95% CI, 1.27 to 2.34; P = .01).
Conclusion
Cisplatin is associated with a significant increase in the risk of VTEs in patients with advanced solid tumors when compared with non–cisplatin-based chemotherapy.
小提示：本篇资讯需要登录阅读，点击跳转登录
版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
#JCO#
48
#铂#
62
#晚期实体瘤#
65
#增高#
53
#增高#
54